NOVEL HIV1 SPECIFIC NON-NUCLEOSIDE RT INHIBITOR
新型 HIV1 特异性非核苷 RT 抑制剂
基本信息
- 批准号:2417554
- 负责人:
- 金额:$ 10万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:1997
- 资助国家:美国
- 起止时间:1997-09-01 至 1998-02-28
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
This proposal is to develop a HIV-1 specific nonnucleoside RT
inhibitor. This compound has been shown to have EC50 values
ranging from 0.4-1.7 microM against both laboratory and clinical HIV-
isolates in the in vitro XTT assay. It is also active against HIV
isolates with a mutation of Y181C, against 3TC-resistant isolates with
an RT mutation of M184I, and against HEPT-resistant isolates with a
mutation of P236L. Furthermore, the compound exhibits potent
activity against human cytomegalovirus with an EC50 value comparable
to that of ganciclovir. Further pharmacological and toxicological
evaluations of the drug will be the focus of this phase I SBIR
program, which include synthesis of one kilogram of (+)-12-
oxocalanolide A, improving the synthetic processes of (+)-12-
oxocalanolide A, and performing the acute single-dose toxicity studies.
The toxicity study will examine oral and intravenous administration of
the inhibitor in two mammalian species, and begin preliminary
pharmacokinetic experiments. The ultimate goal for this SBIR program
will be to file an IND application with the FDA at the end of the
Phase II SBIR and to initiate a Phase I/II clinical trial.
该建议是开发HIV-1特异性非核苷RT
项目成果
期刊论文数量(2)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
In vitro anti-human immunodeficiency virus (HIV) activity of the chromanone derivative, 12-oxocalanolide A, a novel NNRTI.
- DOI:10.1016/s0960-894x(98)00380-1
- 发表时间:1998-08
- 期刊:
- 影响因子:2.7
- 作者:Z. Q. Xu;R. Buckheit;T. L. Stup;M. Flavin;A. Khilevich;J. Rizzo;L. Lin;D. Zembower
- 通讯作者:Z. Q. Xu;R. Buckheit;T. L. Stup;M. Flavin;A. Khilevich;J. Rizzo;L. Lin;D. Zembower
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
ZE-QI XU其他文献
ZE-QI XU的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('ZE-QI XU', 18)}}的其他基金
Nanoscale Metal-Organic Frameworks as X-ray Activatable Cancer Vaccines
纳米级金属有机框架作为 X 射线激活癌症疫苗
- 批准号:
10558960 - 财政年份:2022
- 资助金额:
$ 10万 - 项目类别:
DEVELOPMENT OF NOVEL PHARMACOPHORE WITH ANTI-TB ACTIVITY
具有抗结核活性的新型药效团的开发
- 批准号:
6311243 - 财政年份:2001
- 资助金额:
$ 10万 - 项目类别:
NOVEL PHOSPHONATE NUCLEOTIDE ANALOGS AS ANTIHIV AGENTS
作为抗艾滋病毒药物的新型膦酸酯核苷酸类似物
- 批准号:
2075172 - 财政年份:1995
- 资助金额:
$ 10万 - 项目类别:
SYNTHESIS OF NOVEL ACYCLONUCLEOTIDES AS ANTIHIV AGENTS
作为抗HIV药物的新型环核苷酸的合成
- 批准号:
2074063 - 财政年份:1995
- 资助金额:
$ 10万 - 项目类别:
相似海外基金
ACTG 303--RISK STATUS FOR DISEASE PROGRESSION AND RESPONSE TO ANTIAIDS AGENT
ACTG 303--疾病进展的风险状态和抗艾滋病药物的反应
- 批准号:
6114298 - 财政年份:1998
- 资助金额:
$ 10万 - 项目类别:
ACTG 303--RISK STATUS FOR DISEASE PROGRESSION AND RESPONSE TO ANTIAIDS AGENT
ACTG 303--疾病进展的风险状态和抗艾滋病药物的反应
- 批准号:
6275533 - 财政年份:1997
- 资助金额:
$ 10万 - 项目类别: